BTZ043 – 25 mg

Brand:
Cayman
CAS:
1161233-85-7
Storage:
-20
UN-No:
Non-Hazardous - /

BTZ043 is an antibiotic with antimycobacterial activity.{41991} It targets mycobacterial cell wall synthesis by inhibiting DprE1, which, in conjunction with DprE2, catalyzes the epimerization of decaprenylphosphoryl ribose to decaprenylphosphoryl arabinose. BTZ043 is active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml).{41991,41992} It is also active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection.  

 

Available on backorder

SKU: 22930 - 25 mg Category:

Description

An antibiotic with antimycobacterial activity; targets mycobacterial cell wall synthesis by inhibiting DprE1; active against various Mycobacterium species in vitro, including M. smegmatis, M. bovis, and M. tuberculosis (MICs = 4, 2, and 1 ng/ml, respectively), as well as the actinobacterium N. brasiliensis (MIC50 = 0.125 μg/ml); active against M. tuberculosis in RAW 264.7 murine macrophages (MIC = M. tuberculosis cells in lung and spleen in a mouse model of chronic tuberculosis infection at 37.5 or 300 mg/kg for four weeks


Formal name: 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one

Synonyms: 

Molecular weight: 431.4

CAS: 1161233-85-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antibiotics||Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|Tuberculosis